On 28 May 2024, Bio-Thera and STADA announced they have entered an exclusive commercialisation agreement in relation to BAT2506, biosimilar to Janssen’s Simponi® (golimumab).
Under the agreement, Bio-Thera has responsibility for developing and manufacturing BAT2506, while STADA has exclusive rights to commercialise the product in the EU, UK, Switzerland and certain other unnamed countries. The agreement provides for an upfront payment to Bio-Thera of US$10M, plus milestone payments of up to US$147.5M, subject to fulfillment of certain conditions.
This comes after last month’s announcement by Alvotech of positive topline results from a confirmatory clinical study of its golimumab biosimilar, AVT05.